Enteropathy-associated T cell lymphoma as a complication of longstanding celiac disease

Melika Hosseina, Constantine Soulellis, Alan N. Barkun

ABSTRACT

Abstract is not required for Clinical Images

International Journal of Case Reports and Images (IJCRI)

International Journal of Case Reports and Images (IJCRI) is an international, peer reviewed, monthly, open access, online journal, publishing high-quality, articles in all areas of basic medical sciences and clinical specialties.

Aim of IJCRI is to encourage the publication of new information by providing a platform for reporting of unique, unusual and rare cases which enhance understanding of disease process, its diagnosis, management and clinico-pathologic correlations.

IJCRI publishes Review Articles, Case Series, Case Reports, Case in Images, Clinical Images and Letters to Editor.

Website: www.ijcasereportsandimages.com
Enteropathy-associated T cell lymphoma as a complication of longstanding celiac disease

Melika Hosseina, Constantine Soulellis, Alan N. Barkun

CASE REPORT

A 59-year-old female presented with weight loss, night sweats, and diarrhea since four months. Stool examination, serologic testing, esophagastroduodenoscopy (EGD), colonoscopy (C-scope), and computed tomography (CT) scan of chest and abdomen were non-contributory. Diagnosed with celiac disease at 51, she had had no prior digestive symptoms despite poor adherence to a gluten free diet and persistently positive anti-tissue transglutaminase antibodies. Physical examination revealed cachexia, widespread erythematous maculopapular skin lesions, and no palpable lymphadenopathy. Laboratory examination showed hemoglobin 9.8 g/dL, mean cell volume 92 μm³, white blood cell count 5500/μL (lymphopenia at 300/μL), and serum albumin 2.2 g/dL.

The PET scan showed intense FDG uptake in a left tonsillar mass with multiple FDG-avid subcutaneous lesions, and bowel and mesenteric involvement (Figure 1). The left tonsil and one of the cutaneous lesions were biopsied, revealing a CD8+ T-lymphoid cell infiltrate, most consistent with T cell lymphoma showing a CD4 negative, CD8 positive, and CD 56 negative cytotoxic phenotype. Balloon enteroscopy revealed a mosaiform small bowel mucosa with multiple clean-based ulcers throughout the jejunum. Biopsies were consistent with the tonsillar findings. A few days following admission the patient underwent a laparotomy for small bowel perforation, and was subsequently transferred to the intensive care unit where her course was complicated by recurrent gastrointestinal bleeding, septic shock and respiratory failure, leading to death.

DISCUSSION

Celiac disease (CD) is an immune-mediated enteropathy triggered by ingestion of gluten in genetically
susceptible individuals. It is a common disorder affecting approximately 0.5–1% of Caucasians [1]. Overall, 2–10% of patients with CD develop (RCD) [2]. Refractory celiac disease can be divided into types I (RCD I) and II (RCD II). About half of RCD II patients develop enteropathy-associated T cell lymphoma (EATL) [3]. RCD II is therefore considered an EATL precursor lesion. Although rare, EATL is one of the main causes of death in patients with symptomatic CD diagnosed as adults. In patients with CD presenting with fever, night sweats, pruritus, significant unexplained weight loss, prolonged diarrhea, anorexia, overt or occult gastrointestinal bleeding, abdominal pain, and bowel obstruction, EATL should be sought [1, 3].

Multiple endoscopic or imaging techniques are available to visualize the entire small bowel such as capsule endoscopy, CT or magnetic resonance imaging enterography, deep enteroscopy, and 18F-FDG PET scan. The latter two techniques are of great utility to exclude malignancy in CD patients presenting with alarm features. Abdominal CT scan has shown limited effectiveness in detecting EATL and distinguishing it from uncomplicated refractory celiac disease. Findings of bowel wall thickening, lymphadenopathy, intussusception and hyposplenism raise suspicion for RCD II and EATL. Apart from evidence of metastatic disease there are no well-described CT findings that will distinguish EATL from RCD II. Moreover, the role of radiologic imaging may be limited in diagnosing EATL as the neoplastic changes may be restricted to the epithelial layer of the small bowel, even when the lymphoma affects the whole small intestine [4].

The PET scanning displays higher sensitivity and specificity for the detection of EATL when compared with CT scan [5], but yields false positive results due to increased uptake in inflammatory tissues as is seen in non-refractory CD and RCD. However, the standard uptake value is lower than in EATL (0.0–4.6 vs 6.4–8.0 SUV), making PET a reliable method for identifying EATL [6]. Although PET scanning cannot be a substitute for histologic examination in diagnosing EATL, it may guide histological sampling. Endoscopic examination of the small bowel in patients with celiac disease permits direct visualization and biopsy. Using EGD yields a limited examination of the small bowel, whereas only the distal ileum can be reached with colonoscopy [7]. Deep enteroscopy can provide full-length examination of the small bowel, and the ability to both perform biopsies and deliver therapy [7]. Video capsule endoscopy (VCE) allows full examination of the small bowel and assessment of the extent of involvement. Mucosal flattening and ulcerations can be found in EATL, but are also seen in ulcerative jejunitis. Video capsule endoscopy may also yield false negative results, as EATL can present as a sub-mucosal mass. Thus, reliable detection using VCE may be difficult. Most importantly, detected lesions cannot be sampled at VCE for histological examination [8].

Once a diagnosis of EATL is confirmed, most patients undergo surgical debulking followed by chemotherapy that usually includes the administration of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). If feasible, surgery aids in diagnosis, while also decreasing the risk of potentially lethal perforation following chemotherapy and tumor necrosis. Stem cell transplantation (SCT) may be considered in patients presenting with an overall good clinical state, although no randomized trials have been performed. Unfortunately, as 64% of patients are diagnosed with stage IV disease, the prognosis remains very poor with one and five-year survival rates of 31–39% and 8–20% respectively [1].

CONCLUSION

We present a 59-year-old female with celiac disease of eight years duration who developed weight loss, night sweats, and diarrhea since four months. Biopsies at enteroscopy confirmed an enteropathy-associated T cell lymphoma, noted in 50% of patients with refractory celiac disease type II. As most, she had advanced stage IV disease; she died of small bowel perforation.

Keywords: Celiac disease, Enteropathy-associated T cell lymphoma, Enteroscopy, Positon emission tomography scanning

Acknowledgements

We are thankful to Dr. Giovanni Artho for assistance in securing the PET scan images

Author Contributions

Melika Hosseina – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising
it critically for important intellectual content, Final approval of the version to be published
Constantine Soulellis – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Alan N. Barkun – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published

Guarantor
The corresponding author is the guarantor of submission.

Conflict of Interest
Authors declare no conflict of interest.

Copyright
© 2017 Melika Hosseina et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.

REFERENCES
Edorium Journals: An introduction

About Edorium Journals
Edorium Journals is a publisher of international, high-quality, open access, scholarly journals covering subjects in basic sciences and clinical specialties and subspecialties.

Invitation for article submission
We sincerely invite you to submit your valuable research for publication to Edorium Journals.

Why should you publish with Edorium Journals?
In less than 10 words: “We give you what no one does”.

Vision of being the best
We have the vision of making our journals the best and the most authoritative journals in their respective specialties. We are working towards this goal every day.

Exceptional services
We care for you, your work and your time. Our efficient, personalized and courteous services are a testimony to this.

Editorial review
All manuscripts submitted to Edorium Journals undergo pre-processing review followed by multiple rounds of stringent editorial reviews.

Peer review
All manuscripts submitted to Edorium Journals undergo anonymous, double-blind, external peer review.

Early view version
Early View version of your manuscript will be published in the journal within 72 hours of final acceptance.

Manuscript status
From submission to publication of your article you will get regular updates about status of your manuscripts.

Our Commitment

Six weeks
We give you our commitment that you will get first decision on your manuscript within six weeks (42 days) of submission. If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.

Four weeks
We give you our commitment that after we receive your page proofs, your manuscript will be published in the journal within 14 days (2 weeks). If we fail to honor this commitment by even one day, we will give you a 75% Discount Voucher for your next manuscript.

Favored author program
One email is all it takes to become our favored author. You will not only get 15% off on all manuscript but also get information and insights about scholarly publishing.

Institutional membership program
Join our Institutional Memberships program and help scholars from your institute make their research accessible to all and save thousands of dollars in publication fees.

Our presence
We have high quality, attractive and easy to read publication format. Our websites are very user friendly and enable you to use the services easily with no hassle.

Something more...
We request you to have a look at our website to know more about us and our services. Please visit: www.edoriumjournals.com

We welcome you to interact with us, share with us, join us and of course publish with us.

CONNECT WITH US

Edorium Journals: On Web
Browse Journals

This page is not a part of the published article. This page is an introduction to Edorium Journals.